Opioid-use Disorder, Opioid Withdrawal
Conditions
Keywords
buprenorphine, emergency department
Brief summary
This is a pilot randomized control trial randomizing patients presenting in opioid withdrawal to the emergency department to receive either one of clonidine (usual standard of care) or buprenorphine for their opioid withdrawal. Primary treatment outcome is attendance at a rapid access addiction medicine clinic within a few days of emergency room presentation. Secondary treatment outcome is treatment status with respect to opioid agonist treatment at one month post emergency room visit.
Interventions
DRUGBuprenorphine
The participant receives buprenorphine
DRUGClonidine
The participant receives clonidine
Sponsors
St. Joseph's Health Centre Toronto
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Presenting to the ED in opioid withdrawal or soon to be in withdrawal 2. Minimum age 16 3. English speaking 4. Active phone number 5. Ontario Health Insurance Program card
Exclusion criteria
1. Pregnant 2. Currently enrolled in a methadone or buprenorphine maintenance 3. Benzodiazepine addiction (or taking \>50mg of valium equivalent/day) 4. Acute hepatitis or liver failure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants attending the rapid access clinic | 2-5 days | The number of participants who attend a rapid access clinic assessment after initial enrollment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who are on opioid agonist treatment | 30 days | The number of participants who are maintained on some form of opioid agonist treatment at the one-month mark |
Outcome results
None listed